The registry study aims to determine serial biomarkers to prognosis of Essential Hypertension
The study aims to investigate the role of candidate biomarkers in the prognosis of Essential Hypertension. In the prognosis part of the study, patients with confirmed hypertension are enrolled. The outcome is unstable angina, coronary revascularization, acute myocardial infarction, heart failure, atrial fibrillation, ischemic cerebral infarction, hemorrhagic cerebral infarction, transient ischemic attack, doubling of serum creatinine or end-stage renal disease (defi ned as eGFR less than 15 mL/min/1·73 m² or need for chronic dialysis) and all-cause mortality.
Study Type
OBSERVATIONAL
Enrollment
3,000
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China
RECRUITINGNumber of cardiovascular adverse events
Number of cardiovascular adverse events including unstable angina, coronary revascularization, acute myocardial infarction, heart failure, atrial fibrillation. revascularization, myocardial infarction, heart failure
Time frame: These data is collected from the cases' medical record or during follow-up visit at 1-3 years after discharge.
Number of cerebrovascular adverse events
Number of cerebrovascular adverse events including ischemic stroke and hemorrhagic stroke.
Time frame: These data is collected from the cases' medical record or during follow-up visit at 1-3 years after discharge.
Number of renal adverse events
Number of renal adverse events including Double serum creatinine or end-stage renal disease (eGFR less than 15 mL/min/1.73 m2 or dialysis required).
Time frame: These data is collected from the cases' medical record or during follow-up visit at 1-3 years after discharge.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.